Ilda Bidollari, MD, MBA

  • 2Articles
  • 26.4KReads
  • 2020–2024Active
  • 11Collaborators
  • 21Citations

About

Ilda Bidollari, MD, MBA, is affiliated with Alkermes, Inc. in Waltham, Massachusetts. Her publications from 2020 to 2024 focus on the safety, tolerability, and efficacy of aripiprazole lauroxil formulations in the treatment of schizophrenia and schizoaffective disorders. She has contributed to clinical research on novel dosing regimens and initiation methods for patients transitioning from acute hospitalization to outpatient care.

Publications

JCP
Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months
Original Research

Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months

February 28, 2024

In this post hoc analysis, treatment of acutely exacerbated schizophrenia with aripiprazole lauroxil or paliperidone palmitate was well tolerated, consistent with the safety profiles of these medications.
, , , et al
JCP
Original Research

Aripiprazole Lauroxil to Treat Schizophrenia

May 19, 2020

Read a study examining the efficacy and tolerability of the long-acting injectable (LAI) aripiprazole lauroxil from inpatient into follow-up outpatient care.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe